Best Practice & Research Clinical Haematology
Volume 21, Issue 1 , Pages 43-52, March 2008

Is it important to decipher the heterogeneity of “normal karyotype AML”?

Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, NY 1275 York Avenue, New York, NY 10021, USA

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1521-6926(07)00100-4

doi:10.1016/j.beha.2007.11.010

Best Practice & Research Clinical Haematology
Volume 21, Issue 1 , Pages 43-52, March 2008

Article Tools

* Image Usage & Resolution